Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain
activity and behavior associated with decision-making about rewards (DD task), working memory
and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate
dependent participants initiating buprenorphine. While stably using opiates (initial study
appointment) and again during withdrawal (approximately 3 days later), participants will
receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will
receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve
weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to
the first scanning session, weekly for two weeks and biweekly thereafter.
Participation for all individuals will last 4 months. Assessments will occur at baseline, and
weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second
scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12.
All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will
include a taper).
Phase:
Phase 3
Details
Lead Sponsor:
Butler Hospital
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination